Technical analysis of MetaVia Inc. (MTVA): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH).
Price Performance
| 1 month | +5.37% |
| 3 months | -1.88% |
| Year-to-date | -81.35% |
| 1 year | -86.54% |
52-Week Range
| 52-week High | $14.85 |
| 52-week Low | $0.97 |
| Avg Volume (90d) | 2.7M |
Technical Indicators
| SMA 50 | $1.60 |
| SMA 200 | $2.81 |
| 30-day Volatility (annualised) | 46.5% |
| Price vs SMA 50 | -1.9% |
| Price vs SMA 200 | -44.0% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $10.92 | |
| 2025-11 | $8.56 | -21.6% |
| 2025-12 | $8.42 | -1.6% |
| 2026-01 | $2.43 | -71.1% |
| 2026-02 | $1.51 | -37.9% |
| 2026-03 | $1.20 | -20.5% |
| 2026-04 | $1.44 | +20.0% |
| 2026-05 | $2.84 | +97.2% |
| 2026-06 | $1.43 | -49.6% |
| 2026-07 | $1.42 | -0.7% |
| 2026-08 | $1.72 | +21.1% |
| 2026-09 | $1.57 | -8.7% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $1.54 |
| Market Cap | $3M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.34 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.03 |
| Current Ratio | 2.06 |